ArticleNeuro-oncology2025
TUXEDO-3: A phase 2 trial of patritumab deruxtecan for patients with leptomeningeal metastasis.
Emilie Le Rhun et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
2 papers cite it
this papercites it
ArticleNeuro-oncology2025
Emilie Le Rhun et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.